Percheron Therapeutics Limited
Research Percheron Therapeutics Limited (PER.AX) on Bullrun: market cap AUD 7.93M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPER.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyAUD
- Market capAUD 7.93M
- Financial periodFY2026
- Net income-AUD 4.79M
- Free cash flow-AUD 8.05M
Valuation Snapshot
latest market cap is AUD 7.93M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | n/a | -AUD 4.79M | -AUD 8.05M | n/a | n/a | AUD 4.05M | AUD 27.79K | AUD 7.53M |
| FY2025 | n/a | -AUD 14.92M | -AUD 15.65M | n/a | -0.01 | AUD 10.17M | AUD 25.87K | AUD 10.00M |
| FY2024 | n/a | -AUD 11.92M | -AUD 10.12M | n/a | -0.01 | AUD 11.87M | AUD 39.87K | AUD 9.36M |
| FY2023 | n/a | -AUD 11.38M | -AUD 8.18M | n/a | -0.02 | AUD 10.97M | AUD 142.10K | AUD 9.98M |
| FY2022 | n/a | n/a | n/a | n/a | -0.01 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | AUD 7.93M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Percheron Therapeutics Limited
Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia. Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Percheron Therapeutics Limited's market cap?
Percheron Therapeutics Limited's market capitalization is AUD 7.93M.
What does Percheron Therapeutics Limited do?
Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia. Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.